Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252312 | 0.90 | NPC1 (0.34) | FGFR1KDRMAPTF2PLG | |
| SCHEMBL5250120 | 0.86 | KDR (0.51) | FGFR1KDRF2F12PLAU | |
| SCHEMBL5254347 | 0.85 | FGFR1 (0.55) | FGFR1KDRNPC1RAB9ATUBB4A | |
| SCHEMBL7554927 | 0.82 | KDR (0.44) | FGFR1KDRMAPTNPC1RAB9A | |
| SCHEMBL6282617 | 0.81 | KDR (0.38) | FGFR1KDRNPC1RAB9AVNN1 | |
| SCHEMBL5251050 | 0.79 | FGFR1 (0.45) | FGFR1KDRMAPTNPC1RAB9A | |
| SCHEMBL5251699 | 0.78 | KDR (0.55) | FGFR1KDRLCKPOLB | |
| SCHEMBL5249777 | 0.78 | FGFR1 (0.51) | FGFR1KDRVNN1 | |
| SCHEMBL5250793 | 0.78 | KDR (0.45) | FGFR1KDRLCK | |
| SCHEMBL5247440 | 0.78 | KDR (0.56) | FGFR1KDRNPC1RAB9ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614683-B1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMA (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7141587-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS. INC. | 2005-06-09 | — | — | US | disclosed |
| US-6884890-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | FGFR1 262/4885KDR 60/4885MAPT 812/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | FGFR1 262/4885KDR 60/4885MAPT 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.